KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Short term Debt (2018 - 2020)

Historic Short term Debt for Emergent BioSolutions (EBS) over the last 8 years, with Q2 2020 value amounting to $22.3 million.

  • Emergent BioSolutions' Short term Debt fell 5915.75% to $22.3 million in Q2 2020 from the same period last year, while for Jun 2020 it was $22.3 million, marking a year-over-year decrease of 5915.75%. This contributed to the annual value of $3.2 million for FY2019, which is 6831.68% down from last year.
  • As of Q2 2020, Emergent BioSolutions' Short term Debt stood at $22.3 million, which was down 5915.75% from $3.2 million recorded in Q4 2019.
  • Emergent BioSolutions' 5-year Short term Debt high stood at $62.7 million for Q1 2019, and its period low was $3.2 million during Q4 2019.
  • In the last 3 years, Emergent BioSolutions' Short term Debt had a median value of $38.4 million in 2019 and averaged $34.8 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Short term Debt tumbled by 6831.68% in 2019, and later plummeted by 5915.75% in 2020.
  • Emergent BioSolutions' Short term Debt (Quarter) stood at $10.1 million in 2018, then crashed by 68.32% to $3.2 million in 2019, then surged by 596.88% to $22.3 million in 2020.
  • Its Short term Debt stands at $22.3 million for Q2 2020, versus $3.2 million for Q4 2019 and $55.7 million for Q3 2019.